LCP
VIRX

Lamond Capital Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Lamond Capital Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,286
Closed -$9.43M – 19
2014
Q3 		$9.43M Buy
+6,286
New +$9.1M 10.46% 6

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Lamond Capital Partners's VIRX Position: Q4 2014 in Review

Lamond Capital Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 6,286 shares — an estimated $9.43M sold.

Lamond Capital Partners first reported a position in VIRX in Q3 2014 and held it in 1 quarter. The position peaked at $9.43M in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Lamond Capital Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Lamond Capital Partners sold 6,286 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $9.43M.
  • Lamond Capital Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 1 quarter.
  • Lamond Capital Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $9.43M in Q3 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Lamond Capital Partners's 13F filing for Q4 2014, filed 13 Feb 2015.